Literature DB >> 31073072

Results from HARMONY: an open-label, multicenter, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis.

Simon T Durrant1, Arnon Nagler2, Paola Guglielmelli3, David Lavie4, Philipp le Coutre5, Heinz Gisslinger6, Charles Chuah7, Margherita Maffioli8, Savita Bharathy9, Tuochuan Dong9, Monika Wroclawska10, Joaquin Martinez Lopez11.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31073072      PMCID： PMC6959180          DOI： 10.3324/haematol.2018.209965

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Authors:  Johanna C Bendell; Jordi Rodon; Howard A Burris; Maja de Jonge; Jaap Verweij; Diana Birle; David Demanse; Stefan S De Buck; Qinhua C Ru; Malte Peters; Michael Goldbrunner; José Baselga
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

3.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

Review 4.  Myelofibrosis: an update on drug therapy in 2016.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Expert Opin Pharmacother       Date:  2016-11-07       Impact factor: 3.889

Review 5.  Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.

Authors:  Niccolò Bartalucci; Paola Guglielmelli; Alessandro M Vannucchi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-09

6.  Treatment and management of myelofibrosis in the era of JAK inhibitors.

Authors:  Clodagh Keohane; Deepti H Radia; Claire N Harrison
Journal:  Biologics       Date:  2013-08-20

7.  Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.

Authors:  Meng Ling Choong; Christian Pecquet; Vishal Pendharkar; Carmen C Diaconu; Jacklyn Wei Yan Yong; Shi Jing Tai; Si Fang Wang; Jean-Philippe Defour; Kanda Sangthongpitag; Jean-Luc Villeval; William Vainchenker; Stefan N Constantinescu; May Ann Lee
Journal:  J Cell Mol Med       Date:  2013-11-19       Impact factor: 5.310

8.  Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis.

Authors:  Niccolò Bartalucci; Laura Calabresi; Manjola Balliu; Serena Martinelli; Maria Caterina Rossi; Jean Luc Villeval; Francesco Annunziato; Paola Guglielmelli; Alessandro M Vannucchi
Journal:  Oncotarget       Date:  2017-05-22

9.  mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.

Authors:  Costanza Bogani; Niccolò Bartalucci; Serena Martinelli; Lorenzo Tozzi; Paola Guglielmelli; Alberto Bosi; Alessandro M Vannucchi
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

10.  Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.

Authors:  Niccolò Bartalucci; Lorenzo Tozzi; Costanza Bogani; Serena Martinelli; Giada Rotunno; Jean-Luc Villeval; Alessandro M Vannucchi
Journal:  J Cell Mol Med       Date:  2013-11-17       Impact factor: 5.310
View more
  10 in total

1.  Beyond JAK-STAT: novel therapeutic targets in Ph-negative MPN.

Authors:  Aaron T Gerds
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.

Authors:  Prithviraj Bose
Journal:  Expert Opin Orphan Drugs       Date:  2019-09-24       Impact factor: 0.694

Review 3.  Novel treatments for myelofibrosis: beyond JAK inhibitors.

Authors:  Douglas Tremblay; Ruben Mesa
Journal:  Int J Hematol       Date:  2022-02-19       Impact factor: 2.490

Review 4.  JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis.

Authors:  Andrew T Kuykendall; Rami S Komrokji
Journal:  J Immunother Precis Oncol       Date:  2021-06-22

5.  Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations.

Authors:  Jiajia Yuan; Junzhe Song; Chao Chen; Xue Lv; Jie Bai; Jing Yang; Yuan Zhou
Journal:  Invest New Drugs       Date:  2022-08-31       Impact factor: 3.651

Review 6.  Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis.

Authors:  Andrew T Kuykendall; Nathan P Horvat; Garima Pandey; Rami Komrokji; Gary W Reuther
Journal:  Cancers (Basel)       Date:  2020-08-14       Impact factor: 6.639

Review 7.  Standard care and investigational drugs in the treatment of myelofibrosis.

Authors:  Daniela Barraco; Margherita Maffioli; Francesco Passamonti
Journal:  Drugs Context       Date:  2019-09-26

Review 8.  Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

Authors:  Yammy Yung; Emily Lee; Hiu-Tung Chu; Pui-Kwan Yip; Harinder Gill
Journal:  Int J Mol Sci       Date:  2021-01-11       Impact factor: 5.923

9.  Pharmacological Inhibition of Insulin Growth Factor-1 Receptor (IGF-1R) Alone or in Combination With Ruxolitinib Shows Therapeutic Efficacy in Preclinical Myeloproliferative Neoplasm Models.

Authors:  Titiksha Basu; Hannah Bertrand; Nikolaos Karantzelis; Albert Gründer; Heike L Pahl
Journal:  Hemasphere       Date:  2021-04-30

Review 10.  Next Generation Therapeutics for the Treatment of Myelofibrosis.

Authors:  Douglas Tremblay; John Mascarenhas
Journal:  Cells       Date:  2021-04-27       Impact factor: 6.600
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.